• Home
  • About us
  • History
  • Careers
  • Investor Relations
  • News & Events
  • Contact us
A+ Science
  • Clinical ServicesReduce time to market
    • Continuing Medical Education (CME)
    • POINT Study System
  • PharmacovigilanceSafety first
    • Pharmacovigilance services
  • Outsourcing of ConsultantsEmpower your team
  • About usAbout us
    • Our Vision
    • Our Values
    • Code of Conduct
    • Sustainability
    • Customer Testimonials
    • Our Experience
    • History
    • Careers
    • Investor Relations
    • News & Events
    • Contact us
    • Our Privacy Policy
    • Cookie Policy
  • About us
    • Our Vision
    • Our Values
    • Code of Conduct
    • Sustainability
    • Customer Testimonials
    • Our Experience
    • History
    • Careers
    • Investor Relations
      • Bolagsordning
      • Bolagsstämmor
        • Årsstämma 2025
        • Extra bolagsstämma november 2024
        • Årsstämma 2024
        • Extra bolagssämma september 2023
        • Årsstämma 2023
        • Årsstämma 2022
        • Extra bolagsstämma januari 2022
        • Årsstämma 2021
        • Extra bolagsstämma november 2020
        • Årsstämma 2020
        • Extra bolagsstämma april 2020
        • Årsstämma 2019
        • Årsstämma 2018
        • Årsstämma 2017
        • Årsstämma 2016
    • News & Events
      • News
      • Upcoming Events
      • Past events
    • Contact us
    • Our Privacy Policy
    • Cookie Policy

News

To sign up to our newsletter, complete this form

To end your subscription, unsubscribe from this list



  • 2023
  • / 2022
  • / 2021
  • / 2020
  • / 2019
  • / 2018
  • / 2017
  • / 2016
  • / 2015
  • / 2014
  • / 2013
  • / 2012
  • / 2011
  • / 2010
  • / 2009
  • / 2008
  • / 2007

Owner Vita Nova Ventures acquires SEDOC PM

August 31, 2007
Vita Nova Ventures AB takes over SEDOC Pharmaceutical Medicine AB. SEDOC is a Contract Research Organisation, CRO. The company plans and carries out clinical trials for Swedish and international pharmaceutical, biotechnical and medico-technical companies. The purchase price consists of a cash payment and 110 million Vita Nova Ventures shares. SEDOC will be incorporated into Vita Nova Ventures’ subsidiary A+ Science AB.
Read more

Vita Nova Ventures enters into an agreement of acquisition with SEDOC PM

August 08, 2007
Vita Nova Ventures AB has signed a Letter of Intent for the acquisition of all of the shares in SEDOC Pharmaceutical Medicine AB. SEDOC AB is at present owned by Arandi Development AB. Final negotiations and finalisation of the contract are in progress. If the deal is completed Vita Nova Ventures will take possession on the 31st August 2007. The purchase price will be paid partly in cash and partly in Vita Nova Ventures shares.
Read more
  • Instagram
  • Twitter
  • Linkedin

Copyright © 1997-2025 A+ Science AB - Registered in Sweden - VAT SE556652683501